AMH Is a Good Predictor of Metabolic Risk in Women with PCOS: A Cross-Sectional Study

Abstract

Objective. The relationship between metabolic risk and ovarian function is ambiguous. This retrospective study analyzed the medical records of 461 PCOS patients collected between January 2019 and June 2020 to investigate the relationship between serum anti-Müllerian hormone (AMH) and parameters of metabolic risk in the population with polycystic ovary syndrome (PCOS). Methods. A total of 461 PCOS patients aged 20–40 years were included and stratified into four groups according to the AMH level. The association between AMH and the parameters related to metabolic risk in these groups was compared, and the discrepancies were further explored. Binary logistic regression was performed to examine the risk factors of HOMA-IR. The values of AMH that best predicted the risk of HOMA-IR were also analyzed by ROC curves. Results. AMH was negatively associated with HOMA-IR (odds ratio (OR) −0.279, 95% confidence interval (CI) −0.36 to −0.20), fasting insulin (OR −0.282, 95% CI −0.36 to −0.20), 1-hour postprandial insulin (OR −0.184, 95% CI −0.28 to −0.11), 2-hour postprandial insulin (−0.180, 95%CI −0.28 to −0.11), 3-hour postprandial insulin (OR −0.198, 95% CI –0.30 to −0.13), waist-hip ratio (OR −0.235, 95% CI −0.31 to −0.14), and body mass index (OR −0.350, 95% CI −0.43 to −0.27). There was no statistically significant relationship between blood pressure, serum glucose profile, or lipid levels and AMH. Binary logistic regression showed that AMH protected against the occurrence of PCOS patients (OR: 0.835, 0.776, and 0.898). For the prediction of HOMA-IR, AMH had an AUC-ROC of 0.704 (95% CI 0.652–0.755) with a cutoff value of 7.81 mmol/L, a sensitivity of 70.3%, and a specificity of 70.1%. Conclusions. Higher AMH levels were significantly associated with a lower insulin profile and might be a useful predictor for HOMA-IR in PCOS patients.

Role of antimullarian hormone in the diagnosis of sonographically inconclusive polycystic ovary syndrome

“…A recent study found a strong link between AMH and metabolic syndrome, but not with BP. 26 However, that study excluded patients with obesity. Our study's principal limitations were the limited number of patients and the use of only OV criteria assessed by different routes and sonologists.…”

Short-chain fatty acid-butyric acid ameliorates granulosa cells inflammation through regulating METTL3-mediated N6-methyladenosine modification of FOSL2 in polycystic ovarian syndrome

“…A dysfunction in the immune system affects follicular development or ovulation [ 31 ]. On the other hand, an increase in inflammatory factors in PCOS patients changes the level of AMH, resulting in glucose and lipid metabolism disorder [ 32 , 33 ]. This disorder increases the risk of IR and synthesis of androgens, destroying normal ovulation and fertilization in women.…”

Mechanisms of primordial follicle activation and new pregnancy opportunity for premature ovarian failure patients

“…(Teede et al, 2019;Shrikhande et al, 2020;Vatansever et al, 2020). AMH supplementation is able to maintain follicular reserve in some ovarian injury models, such as chemotherapy-induced premature ovarian failure, polycystic ovary syndrome (PCOS) (Sonigo et al, 2019;Hoyos et al, 2020;Ou et al, 2021;Rudnicka et al, 2021).…”